Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
The UK Advertising Standards Authority said Wahed Invest can no longer run posters with flaming US and EU bills.
It’s part of a collection of measures to address the country’s housing crisis, Spain’s Prime Minister Pedro Sánchez says.
Pershing Square has announced a formal bid for Howard Hughes, the real estate developer where Ackman served as chairman for over a decade.